Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2010 Apr 21

PMID 20405183

Citations 27

Authors

Mohan S Maddur

Shivashankar Othy

Pushpa Hegde

Janakiraman Vani

Sebastien Lacroix-Desmazes

Jagadeesh Bayry

Srini V Kaveri

Affiliations

Soon will be listed here.

Abstract

An altered immune homeostasis as a result of deficiency or defective function of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) is common in several autoimmune diseases. Hence, therapeutic strategies to render Tregs functionally competent are being investigated. Intravenous immunoglobulin (IVIG) is being increasingly used for the treatment of a wide range of autoimmune and inflammatory diseases. Recent studies have demonstrated that IVIG induces the expansion of Tregs and enhances their suppressive functions. These effects of IVIG on Tregs correlate with the beneficial effects of IVIG in patients with autoimmune diseases. Thus, modulation of Tregs by IVIG represents a novel mode of action that explains the therapeutic effects of IVIG in T cell-mediated autoimmune diseases. However, the molecular mechanisms involved in IVIG-mediated modulation of Tregs are unclear and need further investigation.

Citing Articles

A Rare Pediatric Case of Allopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Successfully Treated With Intravenous Immunoglobulins.

Rotulo G, Campanello C, Battaglini M, Bassi M, Pastorino C, Angeletti A J Pediatr Pharmacol Ther. 2024; 29(2):195-199.

PMID: 38596415 PMC: 11001218. DOI: 10.5863/1551-6776-29.2.195.

Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.

Segu-Verges C, Cano S, Calderon-Gomez E, Bartra H, Sardon T, Kaveri S Front Immunol. 2022; 13:901872.

PMID: 36248801 PMC: 9563374. DOI: 10.3389/fimmu.2022.901872.

Protocol of comparison of the effects of single plasma exchange and double filtration plasmapheresis on peripheral lymphocyte phenotypes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a monocentric prospective study with....

Moranne O, Ion I, Cezar R, Messikh Z, Prelipcean C, Chkair S BMC Neurol. 2022; 22(1):293.

PMID: 35931957 PMC: 9354281. DOI: 10.1186/s12883-022-02816-w.

Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.

Perricone C, Triggianese P, Bursi R, Cafaro G, Bartoloni E, Chimenti M Microorganisms. 2021; 9(1).

PMID: 33430200 PMC: 7825648. DOI: 10.3390/microorganisms9010121.

Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.

Maddur M, Lacroix-Desmazes S, Dimitrov J, Kazatchkine M, Bayry J, Kaveri S Clin Rev Allergy Immunol. 2019; 58(2):213-228.

PMID: 31161341 DOI: 10.1007/s12016-019-08746-9.

References

Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G . Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2007; 111(2):715-22. DOI: 10.1182/blood-2007-03-079947. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S . Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008; 105(29):10113-8. PMC: 2481354. DOI: 10.1073/pnas.0711106105. View

Caspi R . Tregitopes switch on Tregs. Blood. 2008; 112(8):3003-4. PMC: 2569158. DOI: 10.1182/blood-2008-08-173609. View

Bayry J, Lacroix-Desmazes S, Kazatchkine M, Kaveri S . Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol. 2007; 3(5):262-72. DOI: 10.1038/ncprheum0481. View

Kessel A, Ammuri H, Peri R, Pavlotzky E, Blank M, Shoenfeld Y . Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007; 179(8):5571-5. DOI: 10.4049/jimmunol.179.8.5571. View

Miyara M, Sakaguchi S . Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007; 13(3):108-16. DOI: 10.1016/j.molmed.2007.01.003. View

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z . CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008; 322(5899):271-5. DOI: 10.1126/science.1160062. View

Sakaguchi S, Yamaguchi T, Nomura T, Ono M . Regulatory T cells and immune tolerance. Cell. 2008; 133(5):775-87. DOI: 10.1016/j.cell.2008.05.009. View

10.

Bayry J, Siberil S, Triebel F, Tough D, Kaveri S . Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today. 2007; 12(13-14):548-52. DOI: 10.1016/j.drudis.2007.05.002. View

11.

Bayry J . Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat Rev Rheumatol. 2009; 5(5):244-5. DOI: 10.1038/nrrheum.2009.77. View

12.

Nimmerjahn F, Ravetch J . Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008; 26:513-33. DOI: 10.1146/annurev.immunol.26.021607.090232. View

13.

De Groot A, Moise L, McMurry J, Wambre E, Van Overtvelt L, Moingeon P . Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood. 2008; 112(8):3303-11. PMC: 2569179. DOI: 10.1182/blood-2008-02-138073. View

14.

Chi L, Wang H, Zhang Y, Wang W . Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol. 2007; 192(1-2):206-14. DOI: 10.1016/j.jneuroim.2007.09.034. View

15.

Andre S, Tough D, Lacroix-Desmazes S, Kaveri S, Bayry J . Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol. 2009; 174(5):1575-87. PMC: 2671245. DOI: 10.2353/ajpath.2009.080987. View

16.

Furuno K, Yuge T, Kusuhara K, Takada H, Nishio H, Khajoee V . CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr. 2004; 145(3):385-90. DOI: 10.1016/j.jpeds.2004.05.048. View

17.

Gold R, Stangel M, Dalakas M . Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007; 3(1):36-44. DOI: 10.1038/ncpneuro0376. View

18.

Tang Q, Bluestone J . The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008; 9(3):239-44. PMC: 3075612. DOI: 10.1038/ni1572. View

19.

Barreto M, Ferreira R, Lourenco L, Moraes-Fontes M, Santos E, Alves M . Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol. 2009; 10:5. PMC: 2656467. DOI: 10.1186/1471-2172-10-5. View

20.

Shevach E . Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009; 30(5):636-45. DOI: 10.1016/j.immuni.2009.04.010. View